JP2018500014A5 - - Google Patents

Download PDF

Info

Publication number: JP2018500014A5
Authority: JP; Japan
Prior art keywords: variable region; chain variable; seq; sequence represented; amino acid
Prior art date: 2015-12-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017529747A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018500014A (ja

JP6892822B2 (ja

Filing date

2015-12-04

Publication date

2019-01-17

2015-12-04 Application filed filed Critical

2015-12-04 Priority claimed from PCT/US2015/064119 external-priority patent/WO2016090327A2/en

2018-01-11 Publication of JP2018500014A publication Critical patent/JP2018500014A/ja

2019-01-17 Publication of JP2018500014A5 publication Critical patent/JP2018500014A5/ja

2020-04-28 Priority to JP2020079303A priority Critical patent/JP6959390B2/ja

2021-06-23 Application granted granted Critical

2021-06-23 Publication of JP6892822B2 publication Critical patent/JP6892822B2/ja

Status Active legal-status Critical Current

2035-12-04 Anticipated expiration legal-status Critical

Links

150000001413 amino acids Chemical class 0.000 claims description 462
125000003275 alpha amino acid group Chemical group 0.000 claims description 224
239000000427 antigen Substances 0.000 claims description 104
102000036639 antigens Human genes 0.000 claims description 104
108091007433 antigens Proteins 0.000 claims description 104
239000012634 fragment Substances 0.000 claims description 63
206010028980 Neoplasm Diseases 0.000 claims description 27
101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 18
102000046935 human TNFRSF17 Human genes 0.000 claims description 18
208000034578 Multiple myelomas Diseases 0.000 claims description 12
206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
210000004027 cell Anatomy 0.000 claims description 12
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
229940127121 immunoconjugate Drugs 0.000 claims description 6
BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 5
102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
208000017604 Hodgkin disease Diseases 0.000 claims description 5
208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 5
208000005017 glioblastoma Diseases 0.000 claims description 5
208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 4
239000013604 expression vector Substances 0.000 claims description 4
150000007523 nucleic acids Chemical class 0.000 claims description 4
102000039446 nucleic acids Human genes 0.000 claims description 4
108020004707 nucleic acids Proteins 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
210000004881 tumor cell Anatomy 0.000 claims description 4
101710112752 Cytotoxin Proteins 0.000 claims description 2
231100000599 cytotoxic agent Toxicity 0.000 claims description 2
239000002619 cytotoxin Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
210000002865 immune cell Anatomy 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 110
238000012986 modification Methods 0.000 description 106
230000004048 modification Effects 0.000 description 106
238000000034 method Methods 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 1

JP2017529747A 2014-12-05 2015-12-04 Ｂ細胞成熟化抗原を標的化する抗体および使用の方法 Active JP6892822B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2020079303A JP6959390B2 (ja)	2014-12-05	2020-04-28	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462088246P	2014-12-05	2014-12-05
US62/088,246		2014-12-05
PCT/US2015/064119 WO2016090327A2 (en)	2014-12-05	2015-12-04	Antibodies targeting b-cell maturation antigen and methods of use

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2020079303A Division JP6959390B2 (ja)	2014-12-05	2020-04-28	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法

Publications (3)

Publication Number	Publication Date
JP2018500014A JP2018500014A (ja)	2018-01-11
JP2018500014A5 true JP2018500014A5 (2)	2019-01-17
JP6892822B2 JP6892822B2 (ja)	2021-06-23

Family

ID=56092678

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2017529747A Active JP6892822B2 (ja)	2014-12-05	2015-12-04	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
JP2020079303A Active JP6959390B2 (ja)	2014-12-05	2020-04-28	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
JP2021132857A Pending JP2021182933A (ja)	2014-12-05	2021-08-17	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2020079303A Active JP6959390B2 (ja)	2014-12-05	2020-04-28	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
JP2021132857A Pending JP2021182933A (ja)	2014-12-05	2021-08-17	Ｂ細胞成熟化抗原を標的化する抗体および使用の方法

Country Status (27)

Country	Link
US (3)	US10562972B2 (2)
EP (2)	EP3872094A3 (2)
JP (3)	JP6892822B2 (2)
KR (2)	KR20240135036A (2)
CN (3)	CN107206076B (2)
AU (2)	AU2015357533B2 (2)
BR (1)	BR112017011914A2 (2)
CA (2)	CA3291403A1 (2)
CY (1)	CY1124096T1 (2)
DK (1)	DK3226897T3 (2)
ES (1)	ES2861925T3 (2)
HR (1)	HRP20210582T1 (2)
HU (1)	HUE053995T2 (2)
IL (2)	IL252624B (2)
LT (1)	LT3226897T (2)
MX (1)	MX2017007246A (2)
NZ (1)	NZ732568A (2)
PH (1)	PH12017501127A1 (2)
PL (1)	PL3226897T3 (2)
PT (1)	PT3226897T (2)
RS (1)	RS61781B1 (2)
RU (1)	RU2766094C2 (2)
SA (1)	SA517381663B1 (2)
SG (2)	SG10201901707QA (2)
SI (1)	SI3226897T1 (2)
SM (1)	SMT202100221T1 (2)
WO (1)	WO2016090327A2 (2)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015357526B2 (en)	2014-12-05	2022-03-17	Eureka Therapeutics, Inc.	Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
KR20240135036A (ko)	2014-12-05	2024-09-10	메모리얼 슬로안 케터링 캔서 센터	B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
CN107995913B (zh)	2015-05-18	2022-02-11	T细胞受体治疗公司	使用融合蛋白对tcr重编程的组合物和方法
EP3842450A1 (en)	2015-10-23	2021-06-30	Eureka Therapeutics, Inc.	Antibody/t-cell receptor chimeric constructs and uses thereof
US20170233484A1 (en)	2016-02-17	2017-08-17	Seattle Genetics, Inc.	Bcma antibodies and use of same to treat cancer and immunological disorders
MA45025A (fr)	2016-05-20	2019-03-27	Lilly Co Eli	Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
EP3494138A1 (en)	2016-08-02	2019-06-12	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
CA3036745A1 (en)	2016-10-07	2018-04-12	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en)	2016-11-22	2023-12-26	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
CN110352068A (zh)	2016-12-02	2019-10-18	南加利福尼亚大学	合成的免疫受体及其使用方法
ES3035979T3 (en) *	2017-01-23	2025-09-11	Crage Medical Co Ltd	Bcma-targeting antibody and use thereof
CN110582509A (zh)	2017-01-31	2019-12-17	诺华股份有限公司	使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
IL268349B2 (en)	2017-02-17	2024-08-01	Hutchinson Fred Cancer Res	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018200585A1 (en)	2017-04-26	2018-11-01	Eureka Therapeutics, Inc.	Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200078404A1 (en)	2017-05-01	2020-03-12	Juno Therapeutics, Inc.	Combination of a cell therapy and an immunomodulatory compound
US20230331827A1 (en) *	2017-07-12	2023-10-19	Maxion Therapeutics Limited	Potassium channel inhibitors
CN111263641B (zh)	2017-08-09	2025-10-31	朱诺治疗学股份有限公司	用于制备基因工程化细胞的方法和组合物
AU2018313950A1 (en)	2017-08-09	2020-02-13	Juno Therapeutics, Inc.	Methods for producing genetically engineered cell compositions and related compositions
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3679370A1 (en)	2017-09-07	2020-07-15	Juno Therapeutics, Inc.	Methods of identifying cellular attributes related to outcomes associated with cell therapy
JP2020533382A (ja)	2017-09-14	2020-11-19	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	癌の組合せ治療
CN111094353A (zh)	2017-09-14	2020-05-01	葛兰素史密斯克莱知识产权发展有限公司	用于癌症的组合治疗
US20200254093A1 (en)	2017-09-14	2020-08-13	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
JP7585034B2 (ja)	2017-10-18	2024-11-18	ノバルティスアーゲー	選択的タンパク質分解のための組成物及び方法
JP7447006B2 (ja)	2017-11-01	2024-03-11	ジュノーセラピューティクスインコーポレイテッド	Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
WO2019089858A2 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
SG11202003657VA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Process for producing a t cell composition
EP3704230B1 (en)	2017-11-01	2024-10-23	Juno Therapeutics, Inc.	Process for generating therapeutic compositions of engineered cells
US11564946B2 (en)	2017-11-01	2023-01-31	Juno Therapeutics, Inc.	Methods associated with tumor burden for assessing response to a cell therapy
US11851679B2 (en)	2017-11-01	2023-12-26	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
AU2018358067A1 (en) *	2017-11-01	2020-05-07	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
SG11202003427XA (en) *	2017-11-06	2020-05-28	Juno Therapeutics Inc	Combination of a cell therapy and a gamma secretase inhibitor
SG11202004512XA (en)	2017-11-15	2020-06-29	Novartis Ag	Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
BR112020010579A2 (pt)	2017-11-30	2020-11-10	Novartis Ag	receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
US20210198372A1 (en)	2017-12-01	2021-07-01	Juno Therapeutics, Inc.	Methods for dosing and for modulation of genetically engineered cells
CA3084446A1 (en)	2017-12-08	2019-06-13	Juno Therapeutics, Inc.	Phenotypic markers for cell therapy and related methods
WO2019113557A1 (en)	2017-12-08	2019-06-13	Juno Therapeutics, Inc.	Process for producing a composition of engineered t cells
JP7433230B2 (ja)	2017-12-08	2024-02-19	ジュノーセラピューティクスインコーポレイテッド	細胞を培養するための無血清培地配合物およびその使用の方法
TW201930591A (zh)	2018-01-08	2019-08-01	瑞士商諾華公司	用於與嵌合抗原受體療法併用之免疫增強rna
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en)	2018-01-31	2020-12-09	Novartis AG	Combination therapy using a chimeric antigen receptor
AU2019214183B2 (en) *	2018-02-01	2022-04-07	Innovent Biologics (Suzhou) Co., Ltd.	Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
WO2019160956A1 (en)	2018-02-13	2019-08-22	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US11993658B2 (en)	2018-03-26	2024-05-28	Sutro Biopharma, Inc.	Anti-BCMA antibodies and treatment methods
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
CN108642085A (zh) *	2018-06-11	2018-10-12	北京安斯晨睿生物科技有限公司	携带bcma突变抗原基因的重组腺相关病毒载体及其构建方法与应用
CA3100187A1 (en)	2018-06-26	2020-01-02	Abl Bio, Inc.	Anti-bcma antibody and use thereof
EP3818083A2 (en)	2018-07-03	2021-05-12	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
TWI838389B (zh)	2018-07-19	2024-04-11	美商再生元醫藥公司	雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD4324851T2 (ro)	2018-07-19	2025-12-31	Regeneron Pharma	Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
EA202190469A1 (ru)	2018-08-09	2021-06-28	Джуно Терапьютикс, Инк.	Способы оценки интегрированных нуклеиновых кислот
CN113474450A (zh)	2018-08-09	2021-10-01	朱诺治疗学股份有限公司	产生工程化细胞的方法以及所述工程化细胞的组合物
CA3109959A1 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3874024A1 (en)	2018-10-31	2021-09-08	Juno Therapeutics GmbH	Methods for selection and stimulation of cells and apparatus for same
CN112955748A (zh)	2018-10-31	2021-06-11	葛兰素史密斯克莱知识产权发展有限公司	治疗癌症的方法
KR20210113169A (ko)	2018-11-01	2021-09-15	주노 쎄러퓨티크스 인코퍼레이티드	Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
MA54079A (fr)	2018-11-01	2021-09-08	Juno Therapeutics Inc	Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
WO2020097403A1 (en)	2018-11-08	2020-05-14	Juno Therapeutics, Inc.	Methods and combinations for treatment and t cell modulation
PL3886875T3 (pl)	2018-11-30	2024-09-09	Juno Therapeutics, Inc.	Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
JP7710373B2 (ja)	2019-02-21	2025-07-18	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en)	2019-02-21	2021-09-16	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
US20220152150A1 (en)	2019-02-25	2022-05-19	Novartis Ag	Mesoporous silica particles compositions for viral delivery
AU2020232691B2 (en)	2019-03-05	2023-06-29	Nkarta, Inc.	CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3942025A1 (en)	2019-03-21	2022-01-26	Novartis AG	Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en)	2019-04-12	2020-10-15	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en)	2019-04-24	2022-08-11	Novartis Ag	Compositions and methods for selective protein degradation
AU2020265741A1 (en)	2019-05-01	2021-11-25	Editas Medicine, Inc.	Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
EP3962519A1 (en)	2019-05-01	2022-03-09	Juno Therapeutics, Inc.	Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
PE20220568A1 (es)	2019-05-21	2022-04-20	Novartis Ag	Moleculas de union a cd19 y usos de las mismas
EP3983006A1 (en)	2019-06-12	2022-04-20	Juno Therapeutics, Inc.	Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
MX2022001065A (es)	2019-07-30	2022-02-14	Shanghai Hansoh Biomedical Co Ltd	Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
BR112022002236A2 (pt)	2019-08-06	2022-05-03	Glaxosmithkline Ip Dev Ltd	Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
JP2022545467A (ja)	2019-08-22	2022-10-27	ジュノーセラピューティクスインコーポレイテッド	Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
CN112574308A (zh) *	2019-09-30	2021-03-30	和铂医药(苏州)有限公司	靶向bcma的抗体、双特异性抗体及其用途
WO2021084050A1 (en)	2019-10-30	2021-05-06	Juno Therapeutics Gmbh	Cell selection and/or stimulation devices and methods of use
WO2021092060A1 (en) *	2019-11-05	2021-05-14	Engmab Sarl	Methods of treatment
PH12022551291A1 (en)	2019-11-26	2023-11-20	Novartis Ag	Chimeric antigen receptors binding bcma and cd19 and uses thereof
WO2021121250A1 (zh) *	2019-12-17	2021-06-24	深圳市菲鹏生物治疗股份有限公司	Bcma结合抗体及其用途
CN113061185B (zh) *	2020-01-02	2023-08-08	益科思特(北京)医药科技发展有限公司	一种bcma抗体的制备方法与应用
CN116234829A (zh)	2020-01-03	2023-06-06	马伦戈治疗公司	抗tcr抗体分子及其用途
JP7456075B2 (ja) *	2020-01-03	2024-03-27	ビオシオンインコーポレイテッド	抗体結合ｂｃｍａ及びその使用
WO2021136323A1 (en) *	2020-01-03	2021-07-08	Salubris (Chengdu) Biotech Co., Ltd.	Antibodies binding bcma and uses thereof
US20230090117A1 (en)	2020-01-28	2023-03-23	Juno Therapeutics, Inc.	Methods for t cell transduction
IL295381B1 (en)	2020-02-12	2026-04-01	Juno Therapeutics Inc	BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
KR20220146530A (ko)	2020-02-27	2022-11-01	노파르티스 아게	키메라 항원 수용체-발현 세포의 제조 방법
KR20220147109A (ko)	2020-02-27	2022-11-02	노파르티스 아게	키메라 항원 수용체 발현 세포의 제조 방법
KR20230009386A (ko)	2020-04-10	2023-01-17	주노 쎄러퓨티크스 인코퍼레이티드	Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN116157125A (zh)	2020-04-28	2023-05-23	朱诺治疗学股份有限公司	针对bcma的t细胞疗法与免疫调节化合物的组合
JP7727662B2 (ja)	2020-05-13	2025-08-21	ジュノーセラピューティクスインコーポレイテッド	臨床応答に関連する特徴量の特定方法およびその使用
AR122546A1 (es)	2020-06-05	2022-09-21	Eisai R&D Man Co Ltd	Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
CA3185455A1 (en)	2020-06-11	2021-12-16	Novartis Ag	Zbtb32 inhibitors and uses thereof
EP4171616A1 (en)	2020-06-26	2023-05-03	Juno Therapeutics GmbH	Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US20230302155A1 (en)	2020-08-21	2023-09-28	Novartis Ag	Compositions and methods for in vivo generation of car expressing cells
JP2023549780A (ja)	2020-11-04	2023-11-29	ジュノーセラピューティクスインコーポレイテッド	改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
JP2024509853A (ja)	2021-03-03	2024-03-05	ジュノーセラピューティクスインコーポレイテッド	Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
KR20230159851A (ko)	2021-03-22	2023-11-22	주노 쎄러퓨티크스 인코퍼레이티드	치료 세포 조성물의 효력을 결정하는 방법
CN117321200A (zh)	2021-03-22	2023-12-29	朱诺治疗学股份有限公司	评估病毒载体颗粒效力的方法
CA3214757A1 (en)	2021-04-08	2022-10-13	Andreas Loew	Multifuntional molecules binding to tcr and uses thereof
KR20230171994A (ko)	2021-04-16	2023-12-21	셀진 코포레이션	선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
IL307612A (en)	2021-04-16	2023-12-01	Celgene Corp	Combined therapies with BCMA-directed T-cell therapy
EP4330381A1 (en)	2021-04-27	2024-03-06	Novartis AG	Viral vector production system
US11931420B2 (en)	2021-04-30	2024-03-19	Celgene Corporation	Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
US20250283037A1 (en)	2021-05-06	2025-09-11	Juno Therapeutics Gmbh	Methods for stimulating and transducing t cells
EP4347656A1 (en)	2021-05-28	2024-04-10	GlaxoSmithKline Intellectual Property Development Limited	Combination therapies for treating cancer
CN113527477B (zh) *	2021-07-23	2023-05-23	河南农业大学	猪源抗PDCoV-N蛋白的scFv及其表达载体、构建方法和应用
TW202323822A (zh)	2021-08-03	2023-06-16	英商葛蘭素史密斯克藍智慧財產發展有限公司	生藥組合物及穩定同位素標記肽之圖譜定位方法
JP2024531364A (ja)	2021-08-20	2024-08-29	ノバルティスアーゲー	キメラ抗原受容体発現細胞を作製する方法
EP4412713A1 (en)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Combination therapies for treating cancer
WO2023081735A1 (en)	2021-11-03	2023-05-11	Celgene Corporation	Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023144702A1 (en)	2022-01-25	2023-08-03	Glaxosmithkline Intellectual Property Development Limited	Combination therapy for cancer
JP2025504002A (ja)	2022-01-28	2025-02-06	ジュノーセラピューティクスインコーポレイテッド	細胞組成物を製造する方法
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2023213969A1 (en)	2022-05-05	2023-11-09	Juno Therapeutics Gmbh	Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en)	2022-05-11	2023-11-16	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en)	2022-05-11	2025-09-25	Celgene Corporation	Methods and uses related to t cell therapy and production of same
EP4532695A1 (en)	2022-05-25	2025-04-09	Celgene Corporation	Methods of manufacturing t cell therapies
WO2023230548A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Method for predicting response to a t cell therapy
CA3263560A1 (en)	2022-08-05	2024-02-08	Juno Therapeutics, Inc.	GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
CN120152717A (zh)	2022-09-08	2025-06-13	朱诺治疗学股份有限公司	T细胞疗法和连续或间歇dgk抑制剂给药的组合
CN120112650A (zh)	2022-10-26	2025-06-06	诺华股份有限公司	慢病毒配制品
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN120882418A (zh) *	2022-11-04	2025-10-31	MiNK治疗公司	B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途
EP4615960A1 (en)	2022-11-09	2025-09-17	C3S2 GmbH	Methods for manufacturing engineered immune cells
EP4630454A1 (en)	2022-12-05	2025-10-15	GlaxoSmithKline Intellectual Property Development Ltd	Methods of treatment using b-cell maturation antigen antagonists
CN121002052A (zh)	2023-02-03	2025-11-21	C3S2 有限公司	用于非病毒生产工程化免疫细胞的方法
WO2024168192A1 (en)	2023-02-10	2024-08-15	Celgene Corporation	Assessment of bcma in biological samples
KR20250169631A (ko)	2023-04-18	2025-12-03	주노 쎄러퓨티크스 인코퍼레이티드	치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
CN121464348A (zh)	2023-05-23	2026-02-03	朱诺治疗学股份有限公司	T细胞的激活标记物和评估t细胞激活的方法
CN117069847B (zh) *	2023-10-08	2024-07-12	北京奇迈永华生物科技有限公司	靶向bcma抗体及其相关产品和医药用途
GB202317065D0 (en)	2023-11-07	2023-12-20	Coding Bio Ltd	BCMA binding molecules
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2025147545A1 (en)	2024-01-03	2025-07-10	Juno Therapeutics, Inc.	Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
WO2026006767A1 (en)	2024-06-28	2026-01-02	Dispatch Biotherapeutics, Inc.	Tethered il-9/il-9r and related engineered cells and methods
WO2026020055A2 (en)	2024-07-18	2026-01-22	Juno Therapeutics, Inc.	Methods for assessing exosomes in a cell composition and related uses
WO2026025092A1 (en)	2024-07-26	2026-01-29	Juno Therapeutics, Inc.	Synthetic promoters for t cell expression
WO2026050572A2 (en)	2024-08-29	2026-03-05	Marengo Therapeutics, Inc.	Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPS6412935A (en)	1987-07-02	1989-01-17	Mitsubishi Electric Corp	Constant-speed travel device for vehicle
UA75049C2 (uk)	1999-08-17	2006-03-15	Байоджен Айдек Ма Інк.	Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
US6436703B1 (en)	2000-03-31	2002-08-20	Hyseq, Inc.	Nucleic acids and polypeptides
AU2001268427B2 (en) *	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
EP1468694A1 (en)	2001-12-27	2004-10-20	Sumitomo Pharmaceuticals Company, Limited	Remedies for anorexia or lifestyle-related diseases and method of screening the same
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US7960518B2 (en) *	2006-06-06	2011-06-14	Crucell Holland B.V.	Human binding molecules having killing activity against enterococci and uses thereof
WO2008105560A1 (ja) *	2007-02-27	2008-09-04	Forerunner Pharma Research Co., Ltd.	抗grp78抗体を有効成分として含む医薬組成物
PT2132230E (pt)	2007-03-22	2014-07-17	Genentech Inc	Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana
DK2356270T3 (da) *	2008-11-07	2016-12-12	Fabrus Llc	Kombinatoriske antistofbiblioteker og anvendelser deraf
EP2406284B9 (en) *	2009-03-10	2017-03-01	Biogen MA Inc.	Anti-bcma antibodies
DK2496698T3 (en)	2009-11-03	2019-04-15	Hope City	TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
EP3459564B1 (en) *	2010-01-06	2021-10-27	Takeda Pharmaceutical Company Limited	Plasma kallikrein binding proteins
JP2011178691A (ja) *	2010-02-26	2011-09-15	Takuya Ueda	カテニン結合プローブとその用途
EP3974453A3 (en)	2010-11-16	2022-08-03	Amgen Inc.	Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US20130101599A1 (en)	2011-04-21	2013-04-25	Boehringer Ingelheim International Gmbh	Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) *	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA033110B1 (ru)	2012-04-11	2019-08-30	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EP2674439B1 (en) *	2012-06-13	2017-02-01	Rottapharm Biotech S.r.l.	Anti-TrkA antibodies, derivatives and uses thereof
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
TW201425336A (zh) *	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) *	2012-12-07	2016-01-26	Amgen, Inc.	BCMA antigen binding proteins
TWI682941B (zh)	2013-02-01	2020-01-21	美商再生元醫藥公司	含嵌合恆定區之抗體
PT2961831T (pt)	2013-02-26	2020-10-12	Memorial Sloan Kettering Cancer Center	Composições e métodos para imunoterapêutica
WO2014191128A1 (en)	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
EP3593812A3 (en)	2014-03-15	2020-05-27	Novartis AG	Treatment of cancer using chimeric antigen receptor
CA2945320A1 (en)	2014-04-10	2015-10-15	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Drug regulated transgene expression
WO2015158671A1 (en)	2014-04-14	2015-10-22	Cellectis	Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI750110B (zh)	2014-07-21	2021-12-21	瑞士商諾華公司	使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
MX2017001079A (es)	2014-07-24	2017-09-12	Bluebird Bio Inc	Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
KR20240135036A (ko)	2014-12-05	2024-09-10	메모리얼 슬로안 케터링 캔서 센터	B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en)	2014-12-05	2022-03-17	Eureka Therapeutics, Inc.	Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EA036379B1 (ru)	2014-12-12	2020-11-02	Блубёрд Био, Инк.	Химерные антигенные рецепторы к bcma
EP3347474B1 (en)	2015-09-11	2020-11-04	Biosceptre (UK) Limited	Chimeric antigen receptors and uses thereof
US20180346571A1 (en)	2015-11-17	2018-12-06	Oncomed Pharmaceuticals, Inc.	Pd-l1-binding agents and uses thereof
WO2018197675A1 (en)	2017-04-28	2018-11-01	Julius-Maximilians-Universität Würzburg	Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
US20200078404A1 (en)	2017-05-01	2020-03-12	Juno Therapeutics, Inc.	Combination of a cell therapy and an immunomodulatory compound
CN107827989A (zh)	2017-10-18	2018-03-23	银丰生物工程集团有限公司	靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
JP7447006B2 (ja)	2017-11-01	2024-03-11	ジュノーセラピューティクスインコーポレイテッド	Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
KR20210113169A (ko)	2018-11-01	2021-09-15	주노 쎄러퓨티크스 인코퍼레이티드	Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법

2015
- 2015-12-04 KR KR1020247028866A patent/KR20240135036A/ko not_active Withdrawn
- 2015-12-04 DK DK15864646.3T patent/DK3226897T3/da active
- 2015-12-04 CN CN201580075520.1A patent/CN107206076B/zh active Active
- 2015-12-04 WO PCT/US2015/064119 patent/WO2016090327A2/en not_active Ceased
- 2015-12-04 NZ NZ732568A patent/NZ732568A/en not_active IP Right Cessation
- 2015-12-04 AU AU2015357533A patent/AU2015357533B2/en not_active Ceased
- 2015-12-04 CN CN202110685552.0A patent/CN113429485A/zh active Pending
- 2015-12-04 SG SG10201901707QA patent/SG10201901707QA/en unknown
- 2015-12-04 BR BR112017011914-5A patent/BR112017011914A2/pt not_active Application Discontinuation
- 2015-12-04 HR HRP20210582TT patent/HRP20210582T1/hr unknown
- 2015-12-04 JP JP2017529747A patent/JP6892822B2/ja active Active
- 2015-12-04 CA CA3291403A patent/CA3291403A1/en active Pending
- 2015-12-04 PL PL15864646T patent/PL3226897T3/pl unknown
- 2015-12-04 CA CA2969877A patent/CA2969877A1/en active Pending
- 2015-12-04 PT PT158646463T patent/PT3226897T/pt unknown
- 2015-12-04 SI SI201531561T patent/SI3226897T1/sl unknown
- 2015-12-04 CN CN202110685571.3A patent/CN113388036A/zh active Pending
- 2015-12-04 KR KR1020177018386A patent/KR102701479B1/ko active Active
- 2015-12-04 LT LTEP15864646.3T patent/LT3226897T/lt unknown
- 2015-12-04 SM SM20210221T patent/SMT202100221T1/it unknown
- 2015-12-04 RS RS20210427A patent/RS61781B1/sr unknown
- 2015-12-04 EP EP20213822.8A patent/EP3872094A3/en active Pending
- 2015-12-04 MX MX2017007246A patent/MX2017007246A/es unknown
- 2015-12-04 HU HUE15864646A patent/HUE053995T2/hu unknown
- 2015-12-04 RU RU2017123549A patent/RU2766094C2/ru active
- 2015-12-04 ES ES15864646T patent/ES2861925T3/es active Active
- 2015-12-04 EP EP15864646.3A patent/EP3226897B1/en active Active
- 2015-12-04 SG SG11201704548PA patent/SG11201704548PA/en unknown
2017
- 2017-06-01 IL IL252624A patent/IL252624B/en unknown
- 2017-06-05 SA SA517381663A patent/SA517381663B1/ar unknown
- 2017-06-05 US US15/613,986 patent/US10562972B2/en active Active
- 2017-06-05 PH PH12017501127A patent/PH12017501127A1/en unknown
2019
- 2019-12-31 US US16/732,089 patent/US10947314B2/en active Active
2020
- 2020-04-28 JP JP2020079303A patent/JP6959390B2/ja active Active
2021
- 2021-02-11 US US17/173,716 patent/US11725059B2/en active Active
- 2021-04-05 CY CY20211100287T patent/CY1124096T1/el unknown
- 2021-08-17 JP JP2021132857A patent/JP2021182933A/ja active Pending
- 2021-09-05 IL IL286124A patent/IL286124A/en unknown
2022
- 2022-01-06 AU AU2022200056A patent/AU2022200056A1/en not_active Abandoned

Publication	Publication Date	Title
JP2018500014A5 (2)	2019-01-17
RU2017123549A (ru)	2019-01-14	Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2018504890A5 (2)	2019-01-17
JP2021527431A5 (2)	2022-06-23
JP2018527919A5 (2)	2019-09-19
JP2019508013A5 (2)	2019-12-05
JP2020513791A5 (2)	2021-04-01
JP2014511179A5 (2)	2015-08-20
JP2015503909A5 (2)	2016-01-28
JP2012525128A5 (2)	2014-05-08
JP2011509245A5 (2)	2012-02-16
JP2017535257A5 (2)	2018-11-08
JP2017529838A5 (2)	2018-10-11
JP2015514110A5 (2)	2016-05-26
JP2016531915A5 (2)	2018-04-12
JP2020502271A5 (2)	2021-02-04
HRP20120701T1 (hr)	2012-10-31	Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2014148502A (ru)	2016-06-27	Человеческие антитела к fel d1 и способы их применения
RU2020120613A (ru)	2021-12-06	Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
RU2016100892A (ru)	2017-07-19	Антитела против tweakr и их применение
JP2015523962A5 (2)	2016-06-16
JPWO2019246514A5 (2)	2022-06-23
RU2017102514A (ru)	2018-07-31	Гуманизированные анти-тау-антитела
JP2015163068A5 (2)	2017-11-16
JP2011501656A5 (2)	2011-11-10